Repackaging of Intravenous Fat Emulsions: A Clinical Conundrum.
Drug Packaging – Methods; Drug Packaging/*methods; Fat Emulsions; Humans; Infant; Intravenous – Administration and Dosage; intravenous fat emulsions; Intravenous/*administration & dosage; Medication Errors – Prevention and Control; Medication Errors/*prevention & control; neonates; Newborn; parenteral nutrition; Parenteral Nutrition – Methods; parenteral nutrition solutions; Parenteral Nutrition/*methods; pediatrics
To accommodate small fluid volumes, repackaging of intravenous fat emulsions (IVFEs) is frequently performed in institutions providing parenteral nutrition to neonates and smaller pediatric patients. However, some consider this an unsafe practice. Concerns for potential administration errors leading to an overdose of IVFEs are weighed against the potential for microbial contamination from the repackaging process. The clinician providing pediatric nutrition support should tailor repackaging practices to ensure patient safety and quality. This discussion aims to describe the strengths and limitations surrounding IVFE repackaging to provide guidance regarding the practice.
Cober M Petrea
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
2016
2016-10
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1177/0884533616662994" target="_blank" rel="noreferrer noopener">10.1177/0884533616662994</a>
Antiphospholipids antibodies in a 12-month-old presenting with idiopathic thrombocytopenic purpura.
Antibodies; Antinuclear/blood/immunology; Antiphospholipid/*blood/immunology; Female; Humans; Idiopathic/*blood/*drug therapy/immunology; Immunoglobulins; Immunologic Factors/*administration & dosage; Infant; Intravenous/*administration & dosage; Purpura; Thrombocytopenic
A 12-month-old Caucasian female with a history of recurrent ear infections presented to the emergency room with petechiae, severe thrombocytopenia (4000/microL), and abnormally prolonged activated partial thromboplastin time. Further autoantibody investigation detected antinuclear antibodies, anti-double-stranded DNA, and antiphospholipid antibodies. Platelet count, in response to intravenous immunoglobulin infusion, increased to more than 100 x 10(3) plt/microL. At 6-month follow-up, no positive autoantibodies were detected.
Nseir Bacel; Panicker Jyoti
Pediatric hematology and oncology
2008
2008-05
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1080/08880010701884733" target="_blank" rel="noreferrer noopener">10.1080/08880010701884733</a>